Universal Screening Program for Cytomegalovirus Infection in the First Trimester of Pregnancy (CITEMB Study)

Launched by FUNDACIO D'INVESTIGACIO EN ATENCIO PRIMARIA JORDI GOL I GURINA · Jan 17, 2023

Keywords

ClinConnect Summary

The CITEMB Study is a clinical trial that is looking at a new screening program for cytomegalovirus (CMV) infection during the first trimester of pregnancy. CMV is a common virus that can sometimes cause health issues for unborn babies, so the goal of this study is to see if screening all pregnant women early in their pregnancy can help identify those at risk and provide better care.

To participate in this study, women need to be at least 16 years old and less than 14 weeks pregnant. If you join the study, you will have a simple blood test to check for CMV. The researchers are currently recruiting participants in Catalonia, Spain, and they want to make sure that you understand everything before you agree to participate. It's important to note that if you have difficulty understanding the information provided or if you're already beyond 14 weeks of pregnancy, you won't be able to join the study. This research could help improve our understanding of CMV and how to support pregnant women and their babies.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • maternal age 16 years or older, and
• • gestational age less than 14 weeks.
• Exclusion Criteria:
• • language barrier preventing informed consent,
• • gestational age at blood sampling above 14 weeks, and
• • consent withdrawal